A multi-biomarker score measures rheumatoid arthritis disease activity in the best study

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1202-1207

  Hirata, Shintaro ^a,b   Dirven, Linda ^a   Shen, Yijing ^c   Centola, Michael ^d   Cavet, Guy ^c   Lems, Willem F ^e   Tanaka, Yoshiya ^b   Huizinga, Thomas W J ^a   Allaart, Cornelia F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Crescendo Bioscience Inc   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bioinformatics; Biomarkers; Cytokines and inflammatory mediators; Disability evaluation; Molecular biology; Outcome measures; Rheumatoid arthritis

Indexed keywords

PLASMA PROTEIN;

ADULT; ALGORITHM; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DISEASE ACTIVITY INDEX; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTI BIOMARKER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX;

BIOINFORMATICS; BIOMARKERS; CYTOKINES AND INFLAMMATORY MEDIATORS; DISABILITY EVALUATION; MOLECULAR BIOLOGY; OUTCOME MEASURES; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CYTOKINES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84879835300     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes362     Document Type: Article

References (20)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
3. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
4. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
5. Tanaka E, Mannalithara A, Inoue E, et al. Efficient management of rheumatoid arthritis significantly reduces longterm functional disability. Ann Rheum Dis 2008;67:1153-8.
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
7. Hallert E, Husberg M, Skogh T. 28-joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatology 2011;50:1259-67.
8. Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials [review]. Nat Clin Pract Rheumatol 2006;2: 611-8.
9. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
10. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis Biological and clinical markers: where are we now?. Arthritis Res Ther 2008;10:208.
11. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012. Advance Access published on 26 June 2012; doi: 10.1002/acr.21767.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
13. Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012, Advance Access published on 12 June 2012; doi: 10.1016/ j.jpba.2012.06.003.
14. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012, Advance Access published on 12 June 2012; doi:10.1136/annrheumdis-2011-200963.
15. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9.
16. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
17. Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology 2004;43:1504-7.
18. Ranzolin A, Brenol JC, Bredemeier M, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794-800.
19. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, health assessment questionnaire (HAQ), multidimensional HAQ (MDHAQ), and routine assessment of patient index data (RAPID) scores. J Rheumatol 2008; 35:603-9.
20. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66: 1443-9.